Stocks Under Scanner in the Biotech Space -- GlycoMimetics, Genocea Biosciences, Inotek Pharma, and Loxo Oncology

NEW YORK, September 5, 2017 /PRNewswire/ --

If you want a Stock Review on GLYC, GNCA, ITEK, or LOXO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Friday, September 01, 2017, the NASDAQ Composite ended the trading session at 6,435.33, up 0.10%; the Dow Jones Industrial Average edged 0.18% higher, to finish at 21,987.56; and the S&P 500 closed at 2,476.55, slightly advancing 0.20%. Gains were broad based as six out of nine sectors ended the day in positive. This Tuesday, DailyStockTracker.com has initiated reports coverage on the following Biotechnology equities: GlycoMimetics Inc. (NASDAQ: GLYC), Genocea Biosciences Inc. (NASDAQ: GNCA), Inotek Pharmaceuticals Corp. (NASDAQ: ITEK), and Loxo Oncology Inc. (NASDAQ: LOXO). Take a look at the free research reports issued today on DailyStockTracker.com for these stocks by signing up at:

http://dailystocktracker.com/register/

GlycoMimetics 

Rockville, Maryland headquartered GlycoMimetics Inc.'s stock finished Friday's session 1.48% lower at $12.02 with a total trading volume of 278,149 shares. The Company's shares have advanced 61.78% over the past twelve months and 97.05% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.17% and 51.89%, respectively. Additionally, shares of GlycoMimetics, which focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the US, have a Relative Strength Index (RSI) of 59.44. Sign up and read the free research report on GLYC at:

http://dailystocktracker.com/registration/?symbol=GLYC

Genocea Biosciences 

On Friday, shares in Cambridge, Massachusetts headquartered Genocea Biosciences Inc. recorded a trading volume of 166,271 shares. The stock ended the session 1.85% higher at $4.96. The Company's shares have advanced 20.39% on an YTD basis. The stock is trading above its 50-day moving average by 0.61%. Moreover, shares of Genocea Biosciences, which engages in developing T cell-directed vaccines and immunotherapies to treat infectious diseases and cancer, have an RSI of 58.44. The complimentary research report on GNCA can be downloaded at:

http://dailystocktracker.com/registration/?symbol=GNCA

Inotek Pharmaceuticals 

Lexington, Massachusetts headquartered Inotek Pharmaceuticals Corp.'s shares closed the day flat at $1.02. The stock recorded a trading volume of 292,268 shares. The Company's shares have gained 9.42% in the last month. The stock is trading below its 50-day moving average by 12.85%. Additionally, shares of Inotek Pharma, which focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the US, have an RSI of 42.02. Register for free on DailyStockTracker.com and access the latest report on ITEK at:

http://dailystocktracker.com/registration/?symbol=ITEK

Loxo Oncology 

Shares in Stamford, Connecticut headquartered Loxo Oncology Inc. finished 1.43% lower at $82.21. The stock recorded a trading volume of 192,747 shares. The Company's shares have advanced 16.07% in the last month, 17.24% in the previous three months, 197.86% over the last twelve months, and 155.99% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.01% and 61.40%, respectively. Furthermore, shares of Loxo Oncology, which develops and sells medicines for patients with genetically defined cancers in the US, have an RSI of 64.56.

On August 29^th, 2017, research firm JMP Securities downgraded the Company's stock rating from 'Market Outperform' to 'Market Perform'. Get free access to your research report on LOXO at:

http://dailystocktracker.com/registration/?symbol=LOXO

--

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@dailystocktracker.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://dailystocktracker.com/disclaimer/

CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: contact@dailystocktracker.com
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE dailystocktracker.com